Back to search

Article

Toripalimab combined with anlotinib as the second-line treatment for advanced hepatocellular carcinoma patients: a prospective, single arm phase II clinical study

2023-06-30

Abstract excerpt

<h4>Background: </h4> The most part of primary liver cancer is hepatocellular carcinoma having a poor prognosis. The treatment strategies including multitarget inhibitors, ICIs, and new options are being explored. Recently studies demonstrated the synergistic effect of anti-angiogenesis-targeted drugs combined with immunotherapy. In this study, we explored toripalimab combined with anlotinib as second-line therapy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a20c8124-85b3-5985-bfdc-e53d53af2137
DOI
10.21203/rs.3.rs-3108453/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Toripalimab combined with anlotinib as the second-line treatment for advanced hepatocellular carcinoma patients: a prospective, single arm phase II clinical studyDOI 10.21203/rs.3.rs-3108453/v1
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.Semantic proximity
Comparing the efficacy of five first-line treatment regimens for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trialsSemantic proximity
Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity
Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.Semantic proximity
Low-dose apatinib and CPT synergistically optimize the tumor microenvironment and enhance the antitumor effects of PD-1 inhibitors in hepatocellular carcinomaSemantic proximity
Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocolSemantic proximity
Comparison of Clinical Efficacy of Molecular Targeted Drugs Combined with Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemoembolization Alone for Primary Liver CancerSemantic proximity
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.Semantic proximity
Survival Analysis of TACE Monotherapy vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort StudySemantic proximity
Screening of HRas, RRas and FOS as Potential Pharmacodynamic Candidates for the Treatment of Hepatocellular CarcinomaSemantic proximity
Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations.Semantic proximity
Preliminary Evaluation of Local Treatment Combined with Systemic Therapy for Tumor Recurrence after Surgery for Dual-Phenotype Hepatocellular CarcinomaSemantic proximity
Select a neighboring publication to make it the new centre.